INTRODUCTION
Bladder contraction during voiding is mediated by the neurotransmitter acetylcholine acting through muscarinic receptors located on urinary bladder smooth muscle cells. At least three subtypes of muscarinic acetylcholine receptors (M 1 , M 2 and M 3 ) can be distinguished based on the actions of relatively subtype selective antimuscarinic agents. Five subtypes arising from five separate genes are identifiable by molecular techniques (5) . Immunologic, functional and molecular studies indicate that most tissues, including the human bladder, contain a mixture of subtypes. Immunoprecipitation has determined that both M 2 and M 3 receptor protein is present in the human bladder (49), however, affinities of subtype selective antimuscarinic agents for inhibition of bladder contractions in neurologically intact animal models including rat, rabbit and mouse are consistent with the M 3 subtype mediating contraction under normal conditions in-vitro (11, 23, 29, 44 ). In the rat, the potency of subtype selective antagonists for inhibition of bladder contraction in-vivo correlates better with their affinity at M 2 , than at M 3 receptors (29) . The affinities of subtype selective antimuscarinic agents for inhibiting in-vitro human bladder contractions have only been published in a few studies using a very small number of specimens (18, 24, 30, 36, 37) . These studies also conclude that, although the M 2 receptor subtype predominates , the minor population of M 3 receptor subtypes mediates contraction of the normal human bladder.
Denervation and spinal cord injury in the rat induce bladder hypertrophy and a change in muscarinic receptor subtype mediating urinary bladder contraction from M 3 to M 2 (7, 11) . Bladder muscle specimens from patients with spinal cord injury were analyzed to determine whether in humans with neurogenic bladder, the muscarinic receptor subtype mediating contraction also shifts from M 3 to the M 2 subtype.
MATERIALS AND METHODS
Studies were performed with approval of the Temple University School of Medicine Institutional Review Board. At the time of open reconstructive surgery, 5 mm X 15 mm full thickness muscle specimens were removed from the bladder dome. A total of 7 bladder specimens were analyzed from 1 male and 6 female patients. Patient characteristics are listed in Table 1 . Six of the patients had traumatic cervical spinal cord injuries (C4-C7) with an average time after injury of 2.6 ± 0.8 yrs. The other patient had an L1 congenital myelomeningocele. The average age of the patients was 18.6 ± 0.7 yrs (range [17] [18] [19] [20] [21] [22] . Pre operative bladder capacity was determined during filling cystometry using a fill rate of 30 ml/min. Bladder capacity was defined as the point at which an uninhibited bladder contraction occurred, or the intravesical pressure reached 40 cm of water pressure whichever came first. Prior to surgery, all patients were being treated with at least one anticholinergic agent for their neurogenic bladders (Table 1 ). In addition, bladder tissue was obtained from 8 organ donors from the National Disease Research Institute (Table 2) were dissected from the specimen under 4 fold magnification such that the direction of the smooth muscle bundles were primarily aligned along the length of the strip. Strips were stretched slowly to 1.0 g of isometric tension in tissue baths containing 15 turnover. This is further supported by a study similar to ours using "normal" human bladders. In these bladder strips, darifenacin had a high pA 2 value similar to that for guinea pig bladder, with low affinities of methoctramine and pirenzepine. The authors concluded that contraction in human bladder is mediated through M 3 receptors, although the exact source of this human tissue and patients characteristics were not specified in this abstract (37). Similarly, in a series of bladder specimens taken from 10 males and 11 females undergoing cystectomy for bladder cancer, the affinities of 6 different muscarinic antagonists (PZP, methoctramine, 4-DAMP, tropicamide, oxybutynin and tolterodine) were consistent with M 3 mediated contractions (18).
Studies in normal bladders from all species studied to date indicate that the M 3 subtype mediates bladder contraction. These determinations are based on the assumption that only one of the receptor subtypes mediates the response. In some of our pathological human bladder specimens from patients with neurogenic bladder dysfunction or organ donors, it appears that both M 2 and M 3 receptors may be mediating the contractile response depending on which subtype selective antagonist was used. We interpret the apparent contradictory data (i.e. a low p-F-HHSiD affinity indicating M 2 mediated contractions together with a low methoctramine affinity indicating (9, 12, 26, 29) . Another issue in determining the muscarinic receptors that mediate normal human bladder contraction is that tissue is taken at the time of surgery performed for some pathologic process, so whether this tissue truly represents normal bladder must be questioned. This also includes organ transplant donor controls, some of which we found in this investigation to have M 2 mediated bladder contractions. A major difference in our study from those published previously is that we are looking at neurogenic bladder which is different from that used in other studies. Irrespective of the physiologic changes from the neurologic injury, another factor to consider in these patients may be the concomitant use of antimuscarinic and other medications.
Prior studies described above have used inactivation of the M 3 receptor with 4-DAMP mustard to produce M 2 mediated contractions (12, 24, 29) . At least 6 of the 7 patients were on long-term antimuscarinics to treat their neurogenic bladders prior to surgery (see table 1 for specifics).
Although these medications do not covalently inactivate the muscarinic receptor like 4-DAMP mustard does, it is possible that the long term use of muscarinic antagonists may serve to modulate the M 3 or M 2 contractile response. Chronic atropine treatment may increase muscarinic receptor density, however, this is dependent on the method of drug administration. When atropine was administered for 14 days through an osmotic pump at 5 mg/kg/day to rats, we found that muscarinic receptor density increased by about 43% (34) . In another study in which atropine was given for 14 days by daily intraperitoneal injection (20 mg/kg), we found that no increase in muscarinic receptor density occurred (17) . The effect of the anti-muscarinics on the density of muscarinic receptors in our patients is unknown. Nonetheless, the only issue that this would cloud is whether contraction in the untreated neurogenic bladder is predominantly mediated by the M 3 receptor. Our data shows that bladder contractions in these patients are mediated by the M 2 receptor, whether it is due to the physiologic changes of the injury, or due to any contribution of their concomitant medications. Another factor in our neurogenic bladder patients may be the effect of functional bladder outlet obstruction from vesico sphincter dyssynergia. Bladder outlet obstruction for 3 days in the rat yields a hypertrophied bladder, some degree of functional denervation and an M 2 mediated component of contraction (9) .
Our data may have clinical implications. In patients with a supra sacral spinal cord injury, some of the bladder contraction can be M 2 mediated. Thus in these patients, addition of a relatively selective M 2 antagonist or a drug which has both M 2 and M 3 blocking activity might be expected to be more effective in increasing bladder capacity than one that is predominantly M 3
selective. However, intravenous administration of the highly M 3 selective antagonist darifenacin has been shown to effectively suppress unstable bladder contractions provoked by rapid fluid infusion (50-100 ml infused at 20 ml/sec) in a group of 8 male patients with supra sacral spinal cord injury (14) . An advantage of an M 2 selective agent would be less dry mouth because salivation is primarily mediated by M 3 receptors (38). On the other hand, an M 2 selective antagonist might be expected to produce increased cardiac side effects since the M 2 receptor mediates the effects of the vagus nerve on the heart. A larger unanswered question is whether these results are applicable to the large number of patients who are clinically neurologically intact and use antimuscarinic medications for overactive bladder. One theory of overactive bladder in otherwise neurologically intact individuals is that of partial detrusor denervation (6) . In our rat model of bladder denervation, there is a shift in the muscarinic receptor subtypes responsible for bladder contraction from M 3 to M 2 . In these patients who have decentralization of their bladders, there was also a shift in the muscarinic receptor subtype mediating contraction from M 3 to M 2 .
These data indicate that if there is some element of denervation in patients with overactive bladder, then there might also be a shift from M 3 to M 2 mediated contraction. This deserves further investigation.
Whereas normal detrusor contractions are thought to be mediated by the M 3 receptor subtype, in patients with neurogenic bladder dysfunction and certain organ donors, contractions can be mediated by the M 2 muscarinic receptor subtype. These findings challenge the assumption upon Table 2 . Organ Donors Figure 2 
